J. Russell Teagarden, DMH
J. Russell Teagarden independently advises prescription drug payer organizations, biopharmaceutical companies, and health care policy centers, and provides methods and reporting expertise for health care research organizations. Until November 2014, he served as Senior Vice President of Medical & Scientific Affairs at the National Organization for Rare Disorders (NORD). His primary roles there mostly concerned research and registry initiatives, clinical intelligence and support functions, education and publication programming, and strategic alliance development. Prior to NORD, he spent 19 years at Medco Health Solutions where he was chiefly involved in managing drug technology assessment, coverage policy development, coverage appeal adjudication, clinical programming development, clinical oversight, and clinical support for the company’s clients and internal departments.
Teagarden has a Bachelor of Science degree in Pharmacy from the University of Illinois College of Pharmacy, a Master of Arts degree in research methodology from Loyola University of Chicago, and a Doctor of Medical Humanities degree from Drew University. He completed a residency in hospital pharmacy at Northwestern University Medical Center and was visiting scholar at the National Institutes of Health Bioethics Department. Teagarden is a research affiliate in the Center of Biomedical Innovation at the Massachusetts Institute of Technology (MIT). He has served as a trustee of the Institute for Safe Medication Practices and the P&T Society. He has served on the Patient Centered Outcomes Research Institute (PCORI) Advisory Panel on Rare Disease and Medicare Evidence Development and Coverage Advisory Committee (MEDCAC), and continues to serve on the Healthcare Quality Expert Committee of the United States Pharmacopeial Convention (USP), the NYU Working Group on Compassionate Use, and the National Advisory Panel of the California Health Benefits Review Program.